Literature DB >> 26300683

Increased treatment-related toxicity subsequent to an anti-PD-1 agent.

Leila Khoja1, Marcus Ortho Butler1, Mary Anne Chappell1, David Hogg1, Anthony M Joshua1.   

Abstract

Entities:  

Year:  2015        PMID: 26300683      PMCID: PMC4530830          DOI: 10.3747/co.22.2418

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  11 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Vemurafenib sensitivity skin reaction after ipilimumab.

Authors:  James J Harding; Melissa Pulitzer; Paul B Chapman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

5.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

7.  Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.

Authors:  Paolo Antonio Ascierto; Ester Simeone; Vanna Chiarion Sileni; Michele Del Vecchio; Paolo Marchetti; Gian Carlo Antonini Cappellini; Ruggero Ridolfi; Francesco de Rosa; Francesco Cognetti; Virginia Ferraresi; Alessandro Testori; Paola Queirolo; Maria Grazia Bernengo; Michele Guida; Luca Galli; Mario Mandalà; Carolina Cimminiello; Gaetana Rinaldi; Fabrizio Carnevale-Schianca; Michele Maio
Journal:  Cancer Invest       Date:  2014-01-31       Impact factor: 2.176

8.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

9.  Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors:  Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

10.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

View more
  5 in total

1.  From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Authors:  Daphne Day; Arta M Monjazeb; Elad Sharon; S Percy Ivy; Eric H Rubin; Gary L Rosner; Marcus O Butler
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

Review 2.  Immune-Mediated Colitis.

Authors:  Tara Menon; Anita Afzali
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

3.  Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Authors:  Samantha Bowyer; Prashanth Prithviraj; Paul Lorigan; James Larkin; Grant McArthur; Victoria Atkinson; Michael Millward; Muoi Khou; Stefan Diem; Sangeetha Ramanujam; Ben Kong; Elizabeth Liniker; Alexander Guminski; Phillip Parente; Miles C Andrews; Sagun Parakh; Jonathan Cebon; Georgina V Long; Matteo S Carlino; Oliver Klein
Journal:  Br J Cancer       Date:  2017-03-21       Impact factor: 7.640

4.  Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.

Authors:  Marcus A Couey; R Bryan Bell; Ashish A Patel; Meghan C Romba; Marka R Crittenden; Brendan D Curti; Walter J Urba; Rom S Leidner
Journal:  J Immunother Cancer       Date:  2019-07-03       Impact factor: 13.751

5.  Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Authors:  S Bowyer; P Prithviraj; P Lorigan; J Larkin; G McArthur; V Atkinson; M Millward; M Khou; S Diem; S Ramanujam; B Kong; E Liniker; A Guminski; P Parente; M C Andrews; S Parakh; J Cebon; G V Long; M S Carlino; O Klein
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.